AGP Executive Report
Last update: 10 hours agoEU Health Approvals: Merck’s KEYTRUDA plus Padcev won a positive CHMP opinion for a new perioperative plan in cisplatin-ineligible resectable muscle-invasive bladder cancer, with an EU decision expected in Q3 2026. Rare Disease Access: Pharming’s Joenja (leniolisib) got EU marketing authorization for activated PI3Kδ syndrome—the first approved option in the bloc—with Germany launch targeted for Q3 2026. India–Nordics Tech Push: Narendra Modi’s Oslo diplomacy is turning into a tech-and-green agenda: a Green Technology and Innovation Strategic Partnership is now institutionalised, and Nordic investment in India is cited as up ~200% over a decade. Liechtenstein Finance Focus: Liechtenstein’s PM told finance leaders stability and continuity matter most as global change accelerates. Public Health Watch: Europe’s STI numbers hit record highs, with England singled out as likely worst-hit by volume. Local Tech/Travel: UK e-gates expand to children aged 8–9 from July 8, aiming to cut airport queue pressure.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.
Perspectify News
.webp)
